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Background: The characterization of induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs)
routinely includes analyses of chromosomal integrity. The belief is that pluripotent stem cells best suited to the
generation of differentiated derivatives should display a euploid karyotype; although, this does not appear to have
been formally tested. While aneuploidy is commonly associated with cell transformation, several types of somatic
cells, including hepatocytes, are frequently aneuploid and variation in chromosomal content does not contribute
to a transformed phenotype. This insight has led to the proposal that dynamic changes in the chromosomal
environment may be important to establish genetic diversity within the hepatocyte population and such diversity
may facilitate an adaptive response by the liver to various insults. Such a positive contribution of aneuploidy to liver
function raises the possibility that, in contrast to existing dogma, aneuploid iPSCs may be capable of generating
hepatocyte-like cells that display hepatic activities.
Results: We examined whether a human iPSC line that had multiple chromosomal aberrations was competent to
differentiate into hepatocytes and found that loss of normal chromosomal content had little impact on the
production of hepatocyte-like cells from iPSCs.
Conclusions: iPSCs that harbor an abnormal chromosomal content retain the capacity to generate hepatocyte–like
cells with high efficiency.
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The availability of human pluripotent stem cells has pro-
vided a cell culture platform for study of human disease
and development [1]. Pluripotent cells could also poten-
tially be used therapeutically as a source of cells for
transplant or drug discovery. Moreover, the finding that
patient–specific pluripotent cells can be relatively easily
generated by molecular reprogramming raises the pro-
spect of using personalized regenerative medicine to
treat a variety of diseases, arguably without fear of im-
mune rejection [2,3]. While the biomedical potential
of pluripotent stem cells is irrefutable, to realize such
potential requires an in depth understanding of the* Correspondence: duncans@mcw.edu
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unless otherwise stated.fundamental properties and complications that are as-
sociated with genomic changes that accompany the re-
programming process. Many studies have revealed that,
as a consequence of reprogramming and stem cell cul-
ture, genetic instability commonly occurs [4]. The gen-
etic variations that have been observed are diverse and
include copy number variations (CNVs), chromosomal
rearrangements, and several sub-chromosomal muta-
tions including deletions and point mutations [5-10].
For pluripotent cells to be used safely in regenerative
medicine, substantial characterization would therefore
be necessary to ensure the genomic integrity of trans-
plantable cells.
Although it is clear that iPSC–derived cells used for
cell therapy should be euploid due to the need for safety,
how chromosomal variation affects the production of
differentiated cells in culture remains ill defined. Cell
differentiation is an orchestrated process that relies ond. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and genetic responses, which establish transcription
factor networks that drive cell fate. With this in mind it
would seem intuitive that aneuploid genomes would be
detrimental to the differentiation of a specific cell type.
However, analyses in both mice and humans have shown
that, unlike most somatic cells, the chromosomal content
of proliferating hepatocytes is diverse and that aneu-
ploidy is commonly observed [11,12]. In liver damage
models it has been established that changes in chromo-
somal content are dynamic with cells constantly gaining
and losing chromosomes. This dynamic nature of chromo-
somal imbalances found in hepatocytes has been referred
to as the ‘ploidy conveyer’ and it has been hypothesized
that the conveyer may facilitate an adaptive response of
hepatocytes to noxious environments [11]. With this
model in mind, it is formally possible that hepatic func-
tion may best be recapitulated if hepatocytes are gener-
ated from iPSCs that display genomic variation. The
generation of polyploidy in rodent hepatocytes begins
after weaning and increases as the animals age; however,
the impact of aneuploidy on hepatocyte differentiation is
unknown. We, therefore, addressed whether hepatocyte-
like cells could be generated from iPSCs that are karyotypi-
cally abnormal.
Results
Characterization of aneuploid iPSCs
We have previously described the generation of a human
iPSC line, referred to as iPSC-K3, which was produced
by reprogramming foreskin fibroblasts using transient
transfection of plasmids that express OCT4, NANOG,
LIN28, and KLF4 [13]. These iPSCs are free of inte-
grated exogenous DNA and have a high capacity to
differentiate into cells that display characteristics of
hepatocytes. The iPSC-K3 cells maintain a stable karyo-
type; however, as with all human pluripotent stem cells,
colonies spontaneously arise that contain chromosomal
variations that presumably support their efficient prolifera-
tion in culture [4].
During routine analyses of a subculture of iPSC-K3
cells we identified a cell line that was extensively aneu-
ploid (Figure 1 and Table 1). In this culture, the majority
of the cells approached a tetraploid state, but included
both gain and loss of discrete chromosomes as well as
chromosomal rearrangements. The composite karyotype
of the line, determined by examination of 19 cells with
consistent abnormalities, is XXYY,-3[19],-6[18],-7[5],-8
[18],-11[16],+12[19],-13[3],-14[4],-15[19],-16[12],-17[5],
dup(17)(q11.2q25)ins(17)(q25;q25q11.2)[19],-18[12],-19
[19],-22[11]. These 19 cells contained 79 ~ 87 chromo-
somes per cell and the frequency of a given chromosomal
imbalance is indicated within the square brackets ([n]).
The major chromosomal imbalances observed were a gainof chromosome 12 and loss of chromosomes 3, 6, 7, 8, 11,
13, 14, 15, 16, 17, 18, 19 and 22. In addition, in all 19 cells
we observed an unbalanced structural abnormality of
chromosome 17 that represented a gain of long (q) se-
quences from chromosome 17 (dup(17)(q11.2q25)ins(17)
(q25;q25q11.2)). Rearrangements of chromosome 17 have
been commonly found in both human ESCs and iPSCs
and are believed to confer advantageous growth in culture
[8]. Although all cells examined were abnormal not all cells
contained every observed rearrangement. Chromosomal
imbalances found in a minority of cells included loss of
chromosomes 7, 13, 14, 18, and 22, raising the possibility
that the culture arose from a mixed population. However,
given that all cells approached tetraploidy, we favor an al-
ternative explanation in which the cells originated clonally
from a single tetraploid event and subsequently diverged in
culture. Figure 1 shows karyograms of the parental iPSC-
K3 line and a single cell from the aneuploid iPSC-K3
(iPSC-K3aneuploid) derivative that contains the majority of
the chromosomal abnormalities that were identified and
Table 1 describes the frequency of each abnormality. In
addition to the majority of the cells that displayed a shared
karyotype, a single non-clonal cell was identified with the
karyotype 66,XXY,+1,+2,-3,+4,+5,+9 + 12,-14,-15,-16, dup
(17)(q11.2q25)ins(17)(q25;q25q11.2),-19,-19,-21,-21,-22.
Despite the abnormal karyotype, the iPSC-K3aneuploid
cells formed colonies that displayed a morphology that
is characteristic of human pluripotent stem cells and im-
munocytochemistry revealed that the majority of cells
within the colonies expressed the pluripotency marker
OCT4 (Figure 1C). In addition, FACS analyses revealed that
close to all of the cells in the culture expressed the pluripo-
tent cell surface markers SSEA-4 (99%) and Tra-1-81
(96%), but not the fibroblast marker CD13 (Figure 1D).
Differentiation of iPSC-K3aneuploid cells to hepatocyte-like
cells
To determine whether iPSCs harboring chromosomal
variation could form hepatocyte–like cells in culture, we
subjected iPSC-K3aneuploid cells to culture conditions
that we have previously demonstrated generates iPSC–
derived cells with hepatocyte characteristics (http://
www.stembook.org/node/721) [14]. The differentiation
process was observed by following the expression of
markers that reflect specific stages of hepatocyte differ-
entiation by immunocytochemistry. Figure 2 shows that
prior to the initiation of differentiation the cells expressed
proteins associated with pluripotency including OCT4,
whereas markers expressed in differentiated cells, such as
SOX17 were not detected (Figure 2, Day 0). To generate
definitive endoderm, Activin A, BMP4, and FGF2 were
added to the culture during the first two days of differenti-
ation, then Activin A alone was included for a subsequent
3 days. At this stage nearly all the cells expressed FOXA2
Figure 1 Characterization of iPS cells with abnormal karyotype. A) Control iPSC-K3 cells were generated from human foreskin fibroblasts
and have a normal diploid male (46, XY) karyotype. B) A sub-line of iPSC-K3 cells, referred to as iPSC-K3aneuploid, have an abnormal near-tetraploid
karyotype as well as rearrangements in chromosome 17 (red arrow). The karyogram presented here is representative of the cells analyzed. C) Left
panel shows a phase contrast micrograph of iPSC-K3aneuploid cells in culture. Immunocytochemistry revealed the presence of OCT4 (middle panel)
and DAPI was used to identify cell nuclei. Scale bar = 100 μm. D) FACS analysis reveals that iPSC-K3aneuploid cells do not express a marker of
differentiated cells, CD13 (left panel); however, pluripotent markers SSEA-4 (middle panel) and Tra-1-81 (right panel) are expressed on the surface of
99% and 96% of the cells, respectively. Isotype controls for each antibody are indicated by the red line, antibodies by the blue line.
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the definitive endoderm (Figure 2, day 5). To generate
hepatic progenitor cells, Activin A was removed from
the medium and replaced with BMP4 and FGF2. After
5 days in culture nearly all of the cells expressed
HNF4a, which is a transcription factor that is expressed
in hepatic progenitor cells and is essential for their dif-
ferentiation to hepatocytes (Figure 2, day 10) [15]. At
this stage, some cells also began to express low levels
of alpha-fetoprotein (AFP), which is another marker of
the early hepatic lineage. After the addition of HGF for
a further 5 days, which induces the hepatic progenitors
to differentiate into fetal hepatocytes, the cells contin-
ued to express HNF4a and the cells increased expression
of AFP, which became easily detected in nearly all of
the cells in the culture (Figure 2, day 15). These fetal
hepatocyte–like cells were then cultured for a further
5 days in Hepatocyte Culture Media supplemented withOncostatin M. By completion of the protocol, nearly all
of the cells expressed Albumin (Figure 2, day 20). During
the differentiation process the morphology of the cells
changed to eventually adopt a cuboidal appearance,
with a high cytoplasmic to nuclear ratio, and evidence
of glycogen granules and lipid vesicles observed in
the cytoplasm (Figure 2). We confirmed that the dif-
ferentiated cells retained an aneuploid phenotype by
performing karyotype analyses after the completion of
the differentiation protocol. As expected, the differenti-
ated cells exhibited a low mitotic index, and very few
cells were in metaphase at the time of cell harvest. A
total of four metaphase cells were recovered; however,
the chromosome morphology was poor and so we were
unable to perform a thorough g-band analysis. Neverthe-
less, the chromosomal content of these cells was poly-
ploid and the cells appeared to have a structural
abnormality tentatively associated with chromosome 17.
Table 1 Chromosomal abnormalities identified in of
iPSC-K3aneuploid cells
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ferentiation we used qRT-PCR to determine the relative
levels of several hepatic mRNAs in primary human he-
patocytes and hepatocyte-like cells derived from either
control iPSC-K3 or from iPSC-K3aneuploid cells in inde-
pendent differentiations (n = 5). As shown in Figure 3,
the levels of APOA1, APOB, CPS1, CYP1A1, FGA, FGG,
GSTA1, HGD, HNF1A, HNF4A, LXR, RXR, SERPINA1,
SLC10A1, TF, and TTR mRNAs could be detected in all
cell types. Although significant differences (p ≤ 0.05) in
the levels of a subset of hepatic mRNAs were observed
between the different lines, the hepatocyte–like cells de-
rived from iPSC-K3aneuploid cells exhibited an overall ex-
pression profile that was very similar to the parental
cells. As we have described previously all iPSC–derived
hepatocytes also retained expression of some fetal
mRNAs including AFP and a number of mRNAs that
are normally expressed in mature hepatocytes, including
CYP3A4, were undetected in both control and iPSC-
K3aneuploid hepatocyte–like cells (data not shown).
Hepatocyte–like cells derived from aneuploid iPSCs retain
functional activities associated with primary hepatocytes
The identification of proteins and mRNAs that are
normally expressed during normal hepatocyte differ-
entiation suggested that aneuploidy did not have a
substantial impact on formation of hepatocytes from
iPSCs. However, we recognized that this was a limited set
of markers and so felt that it was important to determine
whether the differentiated cells displayed activities thatare normally associated with both primary hepatocytes
and hepatocyte–like cells derived from euploid iPSCs
[14,13]. The ability to store glycogen was assessed by
Periodic Acid Schiff staining of cells (Figure 4A), oil red
O staining revealed the presence of lipid droplets within
the differentiated cells (Figure 4B), the cells were capable
of the uptake of Indocyanine Green (Figure 4C), and in-
cubation with fluorescently labeled low-density lipopro-
tein demonstrated the ability of the differentiated
cells to uptake LDL (Figure 4D). Finally, we analyzed
the supernatant in which the differentiated cells
were cultured and observed that the iPSC-K3aneuploid
derived cells effeciently secreted Albumin (Figure 4E) at
levels that were statistically indistinguishable from the
iPSC-K3 derived cells. From these data, we conclude
that the aneuploid status of the iPSC-K3 cells does not
hinder their ability to differentiate into hepatocyte-like
cells.
Discussion
In the current study we have shown that cells with hep-
atocyte characteristics can be generated from iPSCs that
harbor a severely abnormal chromosomal state. Although
from a developmental perspective the successful directed
differentiation of aneuploid iPSCs may seem surprising,
the cells used in the current study retained representative
loci from all chromosomes, albeit in an unbalanced state. It
is likely that as regulatory networks are established during
differentiation they stabilize through cross-regulation and
so chromosomal imbalances may have little impact when
cells are differentiated in culture. The iPSC-K3aneuploid line
also has a heterogeneous karyotype and the observed
chromosomal abnormalities likely reflect the selective pres-
sure of the culture environment. If a specific chromosomal
arrangement were detrimental to cell viability or prolifera-
tion it would be lost during the culture of the pluripotent
cells and if it were detrimental for hepatocyte formation it
potentially could be selected against during the 20–day dif-
ferentiation process.
Although in general it would be deemed prudent to
ensure pluripotent stem cells retain a normal karyotype,
it is possible that for some applications aneuploid cells
could offer advantages. Indeed cancer cells with abnor-
mal karyotypes have been used extensively for the study
of cell function and activity because they can be easily
grown in culture. Since iPSCs with abnormal karyotypes
often grow robustly in culture they could be useful for
applications that require large numbers of cells, such as
drug screening and biochemical applications, especially if
sub-lines can be identified that differentiate particularly
well as a consequence of the chromosomal environment.
In addition, comparative analyses between parental cells
and aneuploid derivatives may be useful for the identifica-
tion of loci that confer specific functional phenotypes,
Figure 2 Generation of hepatocyte–like cells from iPSC-K3aneuploid iPSCs. The top row of panels shows phase contrast microscopy revealing
the changes in morphology that accompany each stage of differentiation. Remaining panels document the result of immunocytochemistry
performed on the cells to detect proteins that are characteristically expressed at specific stages of development. At day 0, prior to adding
differentiation media or growth factors, the cells express OCT4, a marker of pluripotent cells, but do not express SOX17. At day 5, the cells have
formed definitive endoderm, as seen by expression of the endodermal transcription factors FOXA2 and SOX17. At day 10, HNF4a, which is highly
expressed in hepatic progenitor cells, can be identified in the majority of cells in the culture. At the same stage, low levels of AFP, a fetal hepatocyte
marker, can be identified in a subset of cells. By day 15, almost all cells robustly express AFP indicating that they are forming immature hepatocytes. By
the end of the protocol most cells express Albumin, which is highly expressed in adult hepatocytes. Scale bar = 100 μm.
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tocytes this may be particularly relevant given the variation
in ploidy that is observed in adult hepatocytes and the po-
tential contribution of ploidy to hepatocyte function.
Conclusions
To conclude we have demonstrated that a human iPSC
line that has extensive chromosomal abnormalities re-
tains the ability to differentiate into cells that display
hepatocyte characteristics. These data demonstrate that
there exists considerable flexibility in the chromosomal
content that is compatible with differentiation of pluri-
potent cells to the hepatocyte lineage.
Methods
Cell culture
Human iPSCs (iPSC-K3 [13]) were routinely cultured
under low oxygen conditions (4% O2/5% CO2) in hES cell
media (DMEM/F12 medium supplemented with 20%knockout serum replacement (Invitrogen), non essen-
tial amino acids (Invitrogen), glutamine (Invitrogen),
penicillin/streptomycin (Invitrogen) and zbFGF (4 ng/ml))
on mitotically inactivated mouse embryonic fibroblasts
(MEFs). Alternatively, cells were cultured on a recombinant
E-cadherin-IgG Fc fusion protein matrix [16] (StemAdhere,
Primorigen Biosciences, Inc) in MEF-conditioned hES
medium or mTeSR [17]. When cultured on E-cadherin-IgG
Fc, cells were passaged every 4–5 days by non-enzymatic
methods using Versene/EDTA. All work carried out using
human pluripotent stem cells was approved by the MCW
Human Stem Cell Research Oversight Committee (hSCRO
approval# 09–005) and all work performed using animals
was approved by the MCW IACUC.
Hepatocyte-like cell differentiation
Pluripotent cells were differentiated as discussed previously
[14,18]. Briefly, pluripotent cells cultured on E-cadherin-
IgG Fc were harvested using Accutase (Millipore) and
Figure 3 Expression of hepatic mRNAs following differentiation iPSC-K3aneuploid cells. Bar graph showing the relative levels of characteristic
hepatic mRNAs identified by qRT-PCR in fresh human hepatocytes and in hepatocyte–like cells derived from iPSC-K3aneuploid (red bars) and control
iPSC-K3 (parental; blue bars) cells. The level of mRNAs detected in primary human hepatocytes was set to 1 (black dashed line). Specific mRNA
levels in all other samples are presented relative to primary human hepatocytes. Error bars represent the standard deviation recorded from five
(n = 5) independent differentiation experiments and p≤ 0.05 was considered significant (*).
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with 2 mg/ml Matrigel (Geltrex; Invitrogen). Typically,
one 100 mm dish of cells cultured on E-cadherin-IgG Fc
provided enough cells for 2 wells of a 6-well plate. Ap-
proximately 24 hours after seeding the cells onto Matri-
gel, when the cells were 85-95% confluent, differentiation
was initiated by culture for 5 days with 50 ng/ml Activin
A (R&D Systems) in RPMI/B27 (without Insulin) supple-
ment (Invitrogen) under ambient oxygen/5%CO2. In
addition, we included 10 ng/ml BMP4 (Peprotech) and
20 ng/ml FGF-2 (Invitrogen) for the first 2 days. This re-
sulted in reproducible differentiation into definitive
endoderm at efficiencies of greater than 80%. Cells were
cultured for 5 days with 20 ng/ml BMP4 (Peprotech)/
10 ng/ml FGF-2 (Invitrogen) in RPMI/B27 (containing
Insulin) under 4%O2/5%CO2, then 5 days with 20 ng/ml
HGF (Peprotech) in RPMI/B27 (containing Insulin)
under 4%O2/5%CO2, and finally for 5 days with 20 ng/ml
Oncostatin-M (R&D Systems) in Hepatocyte Culture
Media (Lonza) supplemented with SingleQuots (without
EGF) in ambient oxygen/5% CO2.
Karyotype analysis
Pluripotent cells were cultured in T25 flasks coated with
Matrigel in MEF-conditioned media for 2–3 days. Cells
were transported to WiCell Research Institute (Madison,
WI), who performed cell harvest and karyotype analysis
of metaphase chromosomes using G-banding. For karyo-
type analysis of iPS cell-derived hepatocytes, cells were
differentiated on 6-well tissue culture dishes coated withMatrigel. After three days of culture in Hepatocyte Cul-
ture Medium and Oncostatin M, cells were sent to
WiCell Research Institute (Madision, WI) for cell har-
vest and analysis.
Quantitative real-time PCR analysis
Total RNA was collected from cells at each stage of the
differentiation using the RNeasy Mini Kit (Qiagen). Con-
taminating genomic DNA was removed using 1 μl of
RNase-free DNaseI per 5 μg RNA. First strand cDNA
was synthesized using MMLV-RT with dNTPs and ran-
dom hexamer primers. Taqman-based qRT-PCR assays
(PrimeTime) were obtained from IDT (Table 2) and PCR
performed using an Applied Biosystems StepOnePlus™
Real-Time PCR System. All data were collected from re-
actions performed in triplicate.
Enzyme linked immunosorbent assay
Concentration of human albumin in cell culture super-
natant was measured using the Human Albumin ELISA
Quantitation Set (Bethyl; E80-129) according to the manu-
facturer’s instructions. Absorbance (OD) was read on a
plate reader within 15 minutes at 450 nm. Raw values were
converted to concentration based on the standard curve
for each experimental run using ReaderFit (http://www.
readerfit.com).
Periodic acid Schiff staining
For glycogen detection, differentiated cells were fume-fixed
by adding 1 ml PBS with calcium and magnesium to each
Figure 4 Identification of basic hepatocyte functions in cells derived from iPSC-K3aneuploid cells. Top panels show bright-field images with
their corresponding phase contrast images below; scale bar = 100 μm. (A, A’) iPSC-K3 derived hepatocytes are capable of storing glycogen as
shown by periodic acid-Schiff staining. (B, B’) Oil Red O staining demonstrates the cells’ ability to store lipids. (C, C’) Cells can take up indocyanine
green. D) Differentiated cells were incubated with fluoresceinated low-density lipoprotein to demonstrate their ability to internalize LDL. The
corresponding DAPI image is seen in the right panel. E) Bar graph showing levels, measured by ELISA, of human Albumin secreted into the
culture medium from hepatocyte–like cells derived from either parental iPSC-K3 or iPSC-K3aneuploid cells. Error bars represent the standard deviation
recorded from three (n = 3) independent differentiations and no statistically significant difference in Albumin levels (p = 0.45) was observed.
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wells. Fixation occurred by incubation at 37°C for 1 hour.
Cells were permeabilized with 0.4% Triton X-100 in PBS
for 20 minutes at room temperature. Control cells were in-
cubated with Diastase (1 mg/ml in PBS; Sigma) for 1 hour
37°C. Cells were then incubated with Periodic acid (0.5 g
dissolved in 100 ml nano-pure water) for 5 min at room
temperature, washed with distilled water and incubated
with fresh prepared Schiff ’s reagent for 15 min.
Low-density lipoprotein (LDL) uptake
LDL uptake assays were performed as previously described
[19], based on published protocols [20,21]. At the end ofthe differentiation protocol, cells were washed 3 times with
ice-cold PBS, then incubated in ice-cold Hepatocyte
Culture Media containing 5 μg/ml BODIPY® FL LDL
(Invitrogen) for 3.5 hours at 37°C. Unbound LDL was
rinsed away with 5 mg/ml heparin in PBS before imaging.
Indocyanine green uptake
Cellular uptake of indocyanine green (Cardiogreen; Sigma)
was performed using indocyanine green at 1 mg/ml diluted
in Hepatocyte Culture Medium (stock is 5 mg/ml reconsti-
tuted in water, stable for up to 8 hours). Differentiated cells
were incubated for 1 hour at 37°C and rinsed three times
with PBS before imaging.
Table 2 Primers used in real-time qRT-PCR assays
Probe Primer 1 Primer 2
APOA1 CTGCCAGAAATGCCGAGCCTG CTTTGAGCACATCCACGTACA GCCGTGCTCTTCCTGAC
APOB CTGGATACCGTGTATGGAAACTGCTCC CATTGCCCTTCCTCGTCTT CCAGAGACAGAAGAAGCCAAG
CPS1 TCCAGCAATCATTCCGGCCAAGA CCACAGGATTTAAGATACCCCAG GTAATTGTTCAGCCACACCAAG
CYP1A1 TCTGTGATGTCCCGGATGTGGC CCCAACCCTTCCCTGAATG TTCTTCTCCTGACAGTGCTCAATC
FGA CAGGCAGACGATCCTCATGGAAAACA CAGCCCCACCCTTAGAAAAG CTCCTTCAGCTAGAAAGTCACC
FGG AATAAGGGAGCTAAACAGAGCGGGC CAAAGACACGGTGCAAATCC TTCCAGACCCATCGATTTCAC
GSTA1 CGGGCTGACATTCATCTGGTGGA AAATCGCTACTTCCCTGCC GGAAGCTGGAGATAAGACTGG
HGD ATGCAGGCCACTCACAAAGTCTACTT AGCAAGCCATTGTTAGACTT CCTGATCCTAACCAGCTTAGATG
HNF1A CAGGTTGGTGGTGTCGGTGATGA GCCCTCTACAGCCACAAG CAGTGTCTGAGGTGAAGACC
HNF4A CAAGAAATGCTTCCGGGCTGGC ATAGCTTGACCTTCGAGTGC TGGACAAAGACAAGAGGAACC
LXR TGCATAGCTCGTTCCCCAGCATTT CCCTTCAGAACCCACAGAG CGCAGCTCAGAACATTGTAGT
RPL13A AGCAGTACCTGTTTAGCCACGATGG GCCTTCACAGCGTACGA CGAAGATGGCGGAGGTG
RXR AGTACTGCCGCTACCAGAAGTGC AGGACTGCCTGATTGACAAG GACTCCACCTCATTCTCGTTC
SERPINA1 TGGTGCCTGAAGCTGAGGAGAC AGCCAGGGAGACAGGGA CTTAAATACGGACGAGGACAGG
SLC10A1 AACCTCAGCATTGTGATGACCACCT TGTACAGGAGGAGAGGCATC ACCTGTCCAATGTCTTCAGTC
TF CTGTGTCAACTGTGTCCAGGGTGT TGAGCCACGTAAACCTCTTG AGTATTGGTTAAGGGTGGAGC
TTR AGCAGCCTAGCTCAGGAGAAGTGA CAGGTTTGCAGTCAGATTGG CCATCCTGCCAAGAATGAGT
Noto et al. BMC Research Notes 2014, 7:437 Page 8 of 9
http://www.biomedcentral.com/1756-0500/7/437Oil red O staining
For the detection of lipid accumulation, differentiated
cells were fixed with 4% paraformaldehyde in PBS for
20 minutes at room temperature, washed twice with
nano-pure water for 5 minutes, then washed with 60%
2-propanol for 5 minutes. Cells were then incubated for
20 min at room temperature with a freshly prepared
working solution. A 0.5% stock solution of Oil Red O
was prepared by dissolving 0.05 g in 100 ml 2-propanol
and incubating at room temperature overnight. The
working solution contained 60% Oil Red O stock solu-
tion and 40% water, which was allowed to stand for
20 minutes at room temperature and then passed through
a 0.20 μm filter before using. Cell nuclei were then coun-
terstained with hematoxylin.
Immunocytochemistry of cultured cells
Cultured cells were fixed with 4% paraformaldehyde for
20 min at room temperature, made permeable with 0.4%
Triton X-100 in PBS for 15 min and blocked with 3%
BSA in PBS for 1 hour. Cells were incubated overnight
at 4°C with primary antibodies diluted in 1% BSA in
PBS. Primary antibodies used were Oct3/4 (Santa Cruz;
rabbit, 1:500), Sox17 (R&D Systems; goat, 1:250), FoxA2
(Novus Biologicals; Mouse, 1:1000), HNF4a (Santa Cruz;
goat, 1:250), AFP (Sigma; mouse, 1:1000), and Albumin
(DAKO; rabbit, 1:500). Primary antibodies were probed
with respective secondary antibodies conjugated to Alexa
Fluor 488 or 594 (Molecular Probes; 1:1000) and nuclei
were visualized with DAPI.Flow cytometry analysis
Pluripotent iPS cells grown on E-cadherin-IgG Fc were
removed from the plate by incubating with Accutase
(Millipore) for 3 minutes at room temperature. Cells
were blocked with 10% FBS (Gibco) in 1XPBS on ice for
15 minutes, then labeled with antibodies conjugated to
fluorophores diluted 1:20 in 1% FBS (100 μl total) on ice
for 20 minutes. Cells were washed with 1% FBS and re-
suspended in 1% FBS for analysis. Antibodies used were
mouse anti-human CD13-488 (AbD Serotec), mouse
anti-human SSEA-4-PE (Millipore FlowCellect), and
mouse anti-human Tra-1-81-PE (Millipore FlowCellect).
Unstained cells and cells stained with the appropriate
fluorophore-conjugated isotype were used as controls.
Abbreviations
iPSC: Induced pluripotent stem cell; ESC: Embryonic stem cell;
FACS: Fluorescent activated cell sorting; LDL: Low density lipoprotein.
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